Kevin King Net Worth

The estimated Net Worth of Kevin M King is at least $24.4 million dollars as of 4 March 2022. Mr. King owns over 6,815 units of iRhythm Technologies Inc stock worth over $18,739,078 and over the last 8 years he sold IRTC stock worth over $904,146. In addition, he makes $4,774,140 as President, Chief Executive Officer et Director at iRhythm Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. King IRTC stock SEC Form 4 insiders trading

Kevin has made over 22 trades of the iRhythm Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 6,815 units of IRTC stock worth $904,146 on 4 March 2022.

The largest trade he's ever made was exercising 110,000 units of iRhythm Technologies Inc stock on 10 July 2017 worth over $453,200. On average, Kevin trades about 27,133 units every 45 days since 2016. As of 4 March 2022 he still owns at least 250,422 units of iRhythm Technologies Inc stock.

You can see the complete history of Mr. King stock trades at the bottom of the page.

Kevin King biography

Kevin M. King serves as President, Chief Executive Officer, Director of the Company. Mr. King has nearly three decades of experience in the healthcare and IT industries in leadership roles. In January 2007, Mr. King joined Affymetrix, Inc., a publicly traded technology innovator in the field of genetic analysis, as President of Life Sciences Business and Executive Vice President. Mr. King was promoted to President of Affymetrix in September 2007 and then served as President and Chief Executive Officer and a director of Affymetrix from January 2009 until June 2011, leading Affymetrix on a growth strategy into new markets for downstream validation and molecular diagnostics and overseeing several acquisitions. Prior to Affymetrix, from February 2005 until June 2006, Mr. King served as President and Chief Executive Officer of Thomson Healthcare, an information services business which focused on a range of healthcare-related businesses. From March 1997 until November 2004, Mr. King was a senior executive at GE Healthcare, where he led several business units including Magnetic Resonance Imaging and Global Clinical Systems Business. Mr. King began his career at Hewlett-Packard’s Medical Products Group and during his 14-year tenure held leadership roles in Sales, Marketing, R&D, and Business Development. Mr. King holds a B.A. in Economics and Biology from the University of Massachusetts and an M.B.A. from New Hampshire College.

What is the salary of Kevin King?

As the President, Chief Executive Officer et Director of iRhythm Technologies Inc, the total compensation of Kevin King at iRhythm Technologies Inc is $4,774,140. There are no executives at iRhythm Technologies Inc getting paid more.

How old is Kevin King?

Kevin King is 63, he's been the President, Chief Executive Officer et Director of iRhythm Technologies Inc since 2012. There are 5 older and 17 younger executives at iRhythm Technologies Inc. The oldest executive at iRhythm Technologies Inc is Ralph Snyderman, 80, who is the Independent Director.

What's Kevin King's mailing address?

Kevin's mailing address filed with the SEC is C/O INOGEN, INC, 859 WARD DRIVE, GOLETA, CA, 93111.

Insiders trading at iRhythm Technologies Inc

Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi et Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.

What does iRhythm Technologies Inc do?

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Complete history of Mr. King stock trades at Inogen Inc et iRhythm Technologies Inc

iRhythm Technologies Inc executives and stock owners

iRhythm Technologies Inc executives and other stock owners filed with the SEC include:

• Kevin King,
  President, Chief Executive Officer, Director
• David Vort,
  Executive Vice President - Sales
• Mark Day,
  Executive Vice President of Research and Development
• Kevin M. King,
  Consultant & Director
• Matthew C. Garrett,
  Advisor
• Daniel G. Wilson,
  Exec. VP of Strategy, Corp. Devel. & Investor Relations
• Douglas J. Devine,
  COO, CFO & Sec.
• David A. Vort,
  Exec. VP of Sales & Chief Commercial Officer
• Mark J. Day Ph.D.,
  Exec. VP of R&D
• Abhijit Talwalkar,
  Independent Chairman of the Board
• Mark Rubash,
  Independent Director
• Raymond Scott,
  Independent Director
• Bruce Bodaken,
  Independent Director
• Ralph Snyderman,
  Independent Director
• Cathleen Noel Merz,
  Independent Director
• Douglas Devine,
  Chief Financial Officer
• Renee Budig,
  Independent Director
• Mazi Kiani,
  Sr. VP of Quality & Regulatory
• Dietra N. Jones,
  Exec. VP of Clinical Operations
• Reyna M. Fernandez,
  Exec. VP & Chief HR Officer
• Dr. Mintu P. Turakhia M.D.,
  Chief Medical Officer & Chief Scientific Officer
• Allan B. Wilsker,
  Exec. VP of Information Technology & Customer Service
• Patrick Michael Murphy J.D.,
  Gen. Counsel
• Quentin S. Blackford,
  Pres & CEO
• Judith C. Lenane,
  Chief Clinical Officer & Exec. VP of Operations
• Kaja J. Odegard,
  VP of HR
• Marga Ortigas-Wedekind,
  Exec. VP of Marketing
• Michael J. Coyle,
  Pres, CEO & Director
• Tiba Aynechi,
  Director
• Life Science Partners L P S...,
  
• Venture Partners Xi, Lp Cro...,
  
• Matthew C. Garrett,
  Chief Financial Officer
• Life Science Partners L P S...,
  
• Holdings A/S Novo,
  10% owner
• Clercq Casper L. De,
  Director
• Michael J Coyle,
  President and CEO
• Vijay K Lathi,
  Director
• Karim Karti,
  Former Chief Operating Officer
• Derrick Sung,
  EVP, Strat Corp Development
• Mojdeh Poul,
  Director
• Brian B Yoor,
  Director
• Karen Ling,
  Director
• Mervin Smith,
  EVP Strategic Business Ops
• Marc W. Rosenbaum,
  Chief Accounting Officer
• Daniel G. Wilson,
  EVP, Corp Dev Inv Rel
• Brice Bobzien,
  Chief Financial Officer
• Quentin S. Blackford,
  President and CEO
• Minang Turakhia,
  EVP, CMO & CSO
• Reyna M Fernandez,
  EVP, Chief HR Officer
• Chad Patterson,
  Chief Commercial Officer
• Sumi Shrishrimal,
  EVP, Chief Risk Officer
• Patrick Michael Murphy,
  CBO and CLO